Clinical Trial Update: A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating belumosudil for people at risk of graft-versus-host disease after stem cell transplant is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancy

Drugs mentioned

• Belumosudil (belumosudil)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Status: RECRUITING